prikaz prve stranice dokumenta Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
  Download
PDF 299.68 KB
Scientific paper - Original scientific paper
Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
International Journal of Molecular Sciences, 24 (2023), 16; 12840. https://doi.org/10.3390/ijms241612840
Janzic, Urska; Shalata, Walid; Szymczak, Katarzyna; Dziadziuszko, Rafał; Jakopović, Marko; Mountzios, Giannis; Płużański, Adam; Araujo, Antonio; Charpidou, Andriani; Agbarya, Abed

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Janzic, U., Shalata, W., Szymczak, K., Dziadziuszko, R., Jakopović, M., Mountzios, G. ... Agbarya, A. (2023). Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. International Journal of Molecular Sciences, 24. (16). doi: 10.3390/ijms241612840

Janzic, Urska, et al. "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations." International Journal of Molecular Sciences, vol. 24, no. 16, 2023. https://doi.org/10.3390/ijms241612840

Janzic, Urska, Walid Shalata, Katarzyna Szymczak, Rafał Dziadziuszko, Marko Jakopović, Giannis Mountzios, Adam Płużański, Antonio Araujo, Andriani Charpidou and Abed Agbarya. "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations." International Journal of Molecular Sciences 24, no. 16 (2023). https://doi.org/10.3390/ijms241612840

Janzic, U., et al. (2023) 'Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations', International Journal of Molecular Sciences, 24(16). doi: 10.3390/ijms241612840

Janzic U, Shalata W, Szymczak K, Dziadziuszko R, Jakopović M, Mountzios G, and sur.. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations. International Journal of Molecular Sciences [Internet]. 2023 August 16 [cited 2024 August 27];24(16). doi: 10.3390/ijms241612840

U. Janzic, et al., "Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations", International Journal of Molecular Sciences, vol. 24, no. 16, August 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:099032. [Accessed: 27 August 2024]

Metadata
Title (english)Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
AuthorUrska Janzic
AuthorWalid Shalata
AuthorKatarzyna Szymczak
AuthorRafał Dziadziuszko
AuthorMarko Jakopović
AuthorGiannis Mountzios
AuthorAdam Płużański
AuthorAntonio Araujo
AuthorAndriani Charpidou
AuthorAbed Agbarya
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in these cases for the first and second line is not clear. An international registry was created for patients with advanced NSCLC harboring BRAF or cMET exon 14 skipping mutations, diagnosed from January 2017 to June 2022. Clinicopathological and molecular data and treatment patterns were recorded. Data on 58 patients, from eight centers across five countries, were included in the final analysis. We found that 40 patients had the cMET exon 14 skipping mutation and 18 had the BRAF V600E mutation. In total, 53 and 28 patients received first- and second-line treatments, respectively, among which 52.8% received targeted therapy (TT) in the first line and 53.5% in the second line. The overall response rate (ORR) and disease control rate (DCR) for first-line treatment with TT vs. other treatment such as immune checkpoint inhibitors ± chemotherapy (IO ± CT) were 55.6% vs. 21.7% (p = 0.0084) and 66.7% vs. 39.1% (p = 0.04), respectively. The type of treatment in first-line TT vs. other affected time to treatment discontinuation (TTD) was 11.6 m vs. 4.6 m (p= 0.006). The overall survival for the whole group was 15.4 m and was not statistically affected by the type of treatment (19.2 m vs. 13.5 m; p = 0.83).
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleInternational Journal of Molecular Sciences
Numberingvol. 24, no. 16, 12840
e-ISSN1422-0067
DOIhttps://doi.org/10.3390/ijms241612840
URN:NBNurn:nbn:hr:105:099032
Publication2023-08-16
Document URLhttps://www.mdpi.com/1422-0067/24/16/12840
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-08-19 09:06:52